Log in to search using one of your social media accounts:

 

Celebrex vs. Mobic
Title: Celebrex vs. MobicCategory: MedicationsCreated: 11/6/2017 12:00:00 AMLast Editorial Review: 11/6/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - November 6, 2017 Category: Drugs & Pharmacology Source Type: news

Antitumor/Antifungal Celecoxib Derivative AR-12 is a Non-Nucleoside Inhibitor of the ANL-Family Adenylating Enzyme Acetyl CoA Synthetase
AR-12/OSU-03012 is an antitumor celecoxib-derivative that has progressed to Phase I clinical trial as an anticancer agent and has activity against a number of infectious agents including fungi, bacteria and viruses. However, the mechanism of these activities has remained unclear. Based on a chemical-genetic profiling approach in yeast, we have found thatAR-12 is an ATP-competitive, time-dependent inhibitor of yeast acetyl coenzyme A synthetase. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis
Only one new class of antifungal drugs has been introduced into clinical practice in the last 30 years, and thus the identification of small molecules with novel mechanisms of action is an important goal of current anti-infective research. Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity ofAR-12, a celecoxib derivative which has been tested in a phase I clinical trial as an anticancer agent. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche....
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

ESC: No BP Spike Seen with Celecoxib Use
(MedPage Today) -- But ibuprofen boosts systolic pressure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 28, 2017 Category: Cardiology Source Type: news

Ibuprofen associated with blood pressure rise in arthritis patients at cardiovascular risk
(European Society of Cardiology) Ibuprofen is associated with increased blood pressure and hypertension compared to celecoxib in patients with osteoarthritis or rheumatoid arthritis and increased risk of cardiovascular disease, according to late-breaking results from the PRECISION-ABPM study presented today in a Hot Line Session at ESC Congress and published in EHJ. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news

Celecoxib May Be Safest Choice for Older, Chronic NSAID Users Celecoxib May Be Safest Choice for Older, Chronic NSAID Users
The risk of major non-steroidal anti-inflammatory drug (NSAID) toxicity in older adults who take the drugs regularly is higher with naproxen and ibuprofen than with celecoxib, according to a new secondary analysis of PRECISION trial data.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

A cluster of immunoresolvents links coagulation to innate host defense in human blood
Blood coagulation is a protective response that prevents excessive bleeding upon blood vessel injury. We investigated the relationship between coagulation and the resolution of inflammation and infection by lipid mediators (LMs) through metabololipidomics-based profiling of human whole blood (WB) during coagulation. We identified temporal clusters of endogenously produced prothrombotic and proinflammatory LMs (eicosanoids), as well as specialized proresolving mediators (SPMs). In addition to eicosanoids, a specific SPM cluster was identified that consisted of resolvin E1 (RvE1), RvD1, RvD5, lipoxin B4, and maresin 1, each ...
Source: Signal Transduction Knowledge Environment - August 1, 2017 Category: Science Authors: Norris, P. C., Libreros, S., Chiang, N., Serhan, C. N. Tags: STKE Research Resources Source Type: news

COX-2 inhibitors may reverse IDO1-mediated immunosuppression in some cancers
(American Association for Cancer Research) In preclinical studies, tumors that consitutively expressed the protein indoleamine 2,3-dioxygenase (IDO1) responded to the cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) and had improved infiltration of certain subsets of T cells, making them more likely to respond to anti-PD1 therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2017 Category: Cancer & Oncology Source Type: news

Antitumor/Antifungal Celecoxib Derivative AR-12 is a Non-Nucleoside Inhibitor of the ANL-Family Adenylating Enzyme Acetyl CoA Synthetase.
ACS Infect Dis. 2016 Apr 8;2(4):268-280. Epub 2016 Feb 23.Koselny K1, Green J1, Favazzo L1, Glazier VE1, DiDone L1, Ransford S1, Krysan DJ1.AbstractAR-12/OSU-03012 is an antitumor celecoxib-derivative that has progressed to Phase I clinical trial as an anticancer agent and has activity against a number of infectious agents including fungi, bacteria and viruses. However, the mechanism of these activities has remained unclear. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.
Only one new class of antifungal drugs has been introduced into clinical practice in the last 30 years, and thus the identification of small molecules with novel mechanisms of action is an important goal of current anti-infective research. Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity of AR-12, a celecoxib derivative which has been tested in a phase I clinical trial as an anticancer agent. AR-12 inhibits fungal acetyl coenzyme A (acetyl-CoA) synthetase in vitro and is fungicidal at concentrations similar to those achieved in human plasma. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Does chondroitin trump an anti-inflammatory for arthritic knee pain?
A daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn ’t have dangerous side effects, researchers say. (Source: Reuters: Health)
Source: Reuters: Health - June 6, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pharma-Grade Chondroitin Scores for Knee OA (CME/CE)
(MedPage Today) -- Similar to celecoxib in pain relief and function (Source: MedPage Today Pain Management)
Source: MedPage Today Pain Management - May 26, 2017 Category: Anesthesiology Source Type: news

Chondroitin as Effective as Celecoxib for Knee Osteoarthritis (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM High-quality chondroitin sulfate is as effective as celecoxib in treating knee osteoarthritis, according to an international trial in the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 24, 2017 Category: Primary Care Source Type: news

Penn State researchers deliver melanoma drug combo using nanoparticles
Researchers from the Penn State College of Medicine developed a method to deliver a combination of drugs using nanoparticles in the hopes of preventing melanoma cancer cells from developing treatment-resistance. Their work was published in Molecular Cancer Therapeutics and Cancer Letters.  The team’s CelePlum-777 localized around cancer tumors and delivered a specific ratio of an anti-inflammatory, Celecoxib, and a toxin, Plumbagin, the researchers reported. Get the full story at our sister site, Drug Delivery Business News. The post Penn State researchers deliver melanoma drug...
Source: Mass Device - March 16, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Research & Development Penn State College of Medicine Source Type: news

Ibuprofen claimed to raise cardiac arrest risk by a third
Conclusion This study showed an association between taking ibuprofen or diclofenac and an increased risk of a cardiac arrest in the following 30 days, but no association was found with the other NSAIDs investigated. But this study does have its limitations: Although the researchers used the same people to avoid confounding variables, the same person will differ in certain aspects over time – for example, certain diseases may get better or worse, which might have affected the results. The study only looked at prescribed drugs and not over-the-counter drugs. In Denmark, ibuprofen was the only over-the-counter drug ...
Source: NHS News Feed - March 16, 2017 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

Drug combination delivered by nanoparticles may help in melanoma treatment
The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers. CelePlum-777 combines a special ratio of the drugs Celecoxib, an anti-inflammatory, and Plumbagin, a toxin. With the drug, the cells have difficulty overcoming the effect of having more than one active ingredient. (Source: World Pharma News)
Source: World Pharma News - March 15, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Celecoxib: Cardiovascular Risk No Worse Than That of Nonselective NSAIDs
NEW ORLEANS — The cardiovascular safety profile of the nonsteroidal anti-inflammatory drug (NSAID) celecoxib, a selective inhibitor of COX-2, is no worse than those of the nonselective NSAIDs naproxen and ibuprofen, according to a trial reported at the American Heart Association scientific sessions. (Source: Caring for the Ages)
Source: Caring for the Ages - January 31, 2017 Category: Health Management Authors: Susan London Source Type: news

Biomarkers Identified for Celecoxib Chemoprevention in CRC Biomarkers Identified for Celecoxib Chemoprevention in CRC
Potential biomarkers have been identified whichthat may be able to predict response to celecoxib when used as chemoprevention for colorectal cancer (CRC).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study Explores Safety of Celecoxib in Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - January 25, 2017 Category: Orthopaedics Tags: CME Article Source Type: news

Combined Biomarker Expression May Be Significant Driver of Tumorogenisis in Colorectum
Using immunohistochemistry to measure the expression of certain target enzymes —cox-2 and 15-prostaglandin dehydrogenase (15-PGDH)—in premalignant colorectal adenomas, researchers were able to get significant predictive and prognostic information in patients treated with the cox-2 inhibitor celecoxib for prevention of colorectal adenomas. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Colorectal Cancer News Source Type: news

AHA: Study Finds Celebrex Safe for Heart
Results of the PRECISION study are embraced by some and soundly criticized by others. What would you tell your osteoarthritis patients? (Source: ConsultantLive)
Source: ConsultantLive - December 2, 2016 Category: Internal Medicine Authors: Peggy Peck Tags: Cardiovascular Diseases Source Type: news

With No Increase in Heart Risk, Will You Prescribe Celebrex?
(MedPage Today) -- The cardiovascular risk cloud has been lifted -- will it make a difference? (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 28, 2016 Category: American Health Source Type: news

Morning Rounds: Celebrex, statins, and more
CBS News chief medical correspondent Dr. Jon LaPook looks at a new study that says the Celebrex arthritis drug does not pose a greater heart risk than rival drugs. Also, he is joined by CBS News contributor Dr. Tara Narula on "CBS This Morning: Saturday" to discuss recommendations for the use of the statin drugs to lower the risk of heart disease, and more. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 19, 2016 Category: Consumer Health News Source Type: news

Doctor on new Celebrex study: "Everybody was wrong – including me"
Researchers spent a decade studying the arthritis drug Celebrex to see if it causes heart problems, and now the surprising results are in (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news

PRECISION Results Open The Door For OTC Celebrex
They are highly motivated and will know quickly if OTC Celebrex is working for them or not. This is an ideal situation for an OTC drug. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 15, 2016 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE Source Type: news

Celebrex May Not Pose Bigger Heart Risk Than Similar Drugs: Study
Title: Celebrex May Not Pose Bigger Heart Risk Than Similar Drugs: StudyCategory: Health NewsCreated: 11/14/2016 12:00:00 AMLast Editorial Review: 11/15/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - November 15, 2016 Category: Cardiology Source Type: news

Celebrex study shows less risk to heart health than expected
Researchers spend a decade studying Celebrex, an arthritis drug, to see if it causes heart problems. A similar drug was removed from the market in 2004, as it increased the risk of heart attack and stroke. Dr. Jon LaPook reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news

Doctor on new Celebrex study: "Everybody was wrong -- including me"
Researchers spent a decade studying the arthritis drug Celebrex to see if it causes heart problems, and now the surprising results are in (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news

Bad News for Naproxen in RA
(MedPage Today) -- PRECISION study gives boost to Celebrex for RA (but not OA) patients (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 14, 2016 Category: Geriatrics Source Type: news

Celebrex May Not Pose More Heart Risk Than Others
Researchers found more complications, such as bleeding, for the pain relievers ibuprofen and naproxen (Source: WebMD Health)
Source: WebMD Health - November 14, 2016 Category: Consumer Health News Source Type: news

Celebrex May Not Pose Bigger Heart Risk Than Similar Drugs: Study
Researchers found more complications, such as bleeding, for the pain relievers ibuprofen and naproxen Source: HealthDay Related MedlinePlus Pages: Heart Diseases, Pain Relievers (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 14, 2016 Category: Consumer Health News Source Type: news

Celebrex Is No Riskier For Heart Than Other Arthritis Drugs, Study Finds
NEW ORLEANS (AP) — A new study gives some reassurance to arthritis sufferers who want pain relief but are worried about side effects. It finds that Celebrex, a drug similar to ones withdrawn 12 years ago for safety reasons, is no riskier for the heart than some other prescription pain pills that are much tougher on the stomach. “We do not want patients to suffer with pain and we need to know what is safe to give them,” said Dr. Steven Nissen, the Cleveland Clinic’s heart chief, who led the study. Fear that Celebrex would be worse than alternatives proved unfounded, and “on almost every endpoin...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 14, 2016 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Arthritis Celebrex Source Type: news

Study Suggests Celebrex Isn't Riskier Than Rival Pain Drugs
A major study of drugs used to treat arthritis pain challenges some long-held assumptions about the safety of pills taken by millions of patients world-wide. (Source: WSJ.com: Health)
Source: WSJ.com: Health - November 14, 2016 Category: Pharmaceuticals Tags: FREE Source Type: news

Arthritis drug Celebrex not as risky for heart as suspected, study finds
Some of the more than 50 million Americans with arthritis may benefit from data published in the New England Journal of Medicine showing the popular arthritis painkiller Celebrex is just as safe as drugs like ibuprofen and naproxen. CBS News medical contributor Dr. Tara Narula, a cardiologist at Lenox Hill Hospital in New York, joins "CBS This Morning" to discuss the findings. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 14, 2016 Category: Consumer Health News Source Type: news

Celebrex May Not Pose Bigger Heart Risk Than Similar Drugs: Study
MONDAY, Nov. 14, 2016 -- Some people taking the pain reliever Celebrex may not have a greater risk for heart problems than those taking other nonsteroidal anti-inflammatory drugs (NSAIDs), a new study says. Celebrex (celecoxib) is a COX-2... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2016 Category: Journals (General) Source Type: news

Surprise! Arthritis Drug Celebrex Shown As Safe As Ibuprofen and Naproxen
PRECISION has helped physicians and patients better understand the risks and benefits of the drugs used to treat arthritis pain. They have Pfizer to thank for that. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 14, 2016 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: NYSE:PFE NYSE:MRK Source Type: news

Heart experts "stunned" by results of Celebrex drug study
A new study that evaluated Celebrex for cardiac risks may change how doctors treat heart patients with arthritis (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 14, 2016 Category: Consumer Health News Source Type: news

Heart experts "stunned" by results of drug study
A new study that evaluated Celebrex for cardiac risks may change how doctors treat heart patients with arthritis (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 14, 2016 Category: Consumer Health News Source Type: news

Good news for Celebrex users
A large study trying to determine a link between the anti-inflammatory drug Celebrex and heart problems has concluded. The results of the study have shocked doctors, but in a good way. Dr. Jon LaPook has more. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 14, 2016 Category: Consumer Health News Source Type: news

PRECISION: Celecoxib Similar to Ibuprofen, Naproxen for CV Risk PRECISION: Celecoxib Similar to Ibuprofen, Naproxen for CV Risk
Celecoxib hit its noninferiority CV mark against ibuprofen and naproxen in arthritis patients at increased CVD risk, but not all are convinced.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Study Suggests Celebrex Isn't Riskier Than Rivals
A major study of drugs used to treat arthritis pain challenges some long-held assumptions about the safety of pills taken by millions of patients world-wide. But limitations of the data led some researchers to question the results. (Source: WSJ.com: Health)
Source: WSJ.com: Health - November 13, 2016 Category: Pharmaceuticals Tags: FREE Source Type: news

Celecoxib Seems to Carry No Greater CV Risk Than Nonselective NSAIDs in Patients with Arthritis (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH The COX-2 inhibitor celecoxib does not confer greater cardiovascular risk than nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with arthritis, according to an industry-supported, noninferiority trial. The findings were published on Sunday in the New Engl and Journal of Medicine … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 13, 2016 Category: Primary Care Source Type: news

Pfizer's Celebrex shown to be as safe as ibuprofen or naproxen: study
NEW ORLEANS (Reuters) - Pfizer Inc's Celebrex arthritis drug was shown to be at least as safe as the widely used prescription-strength versions of painkillers ibuprofen and naproxen, and does not appear to cause heart problems that spurred the withdrawal of rival Vioxx, according to a large 10-year study presented on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Are Naproxen And Ibuprofen Sometimes Risky? A Controversial Study Of Celebrex Raises Concerns
A study released today may mean that the painkiller celecoxib, once sold under the brand name Celebrex, is safer than prescription doses of ibuprofen or naproxen. That is if the study, which is already controversial, means anything at all. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 13, 2016 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:PFE NYSE:MRK NYSE:BAY NYSE:JNJ Source Type: news

10-year study eases concerns about Celebrex, heart risk
(Source: CNN.com - Health)
Source: CNN.com - Health - November 13, 2016 Category: Consumer Health News Source Type: news

Surprising new findings about pain relievers taken by ‘ everyone on the planet ’
Celebrex poses no more risks of heart problems than ibuprofen or naproxen. Ibuprofen Related:New statin guidelines: Everyone 40 and older should be considered for the drug therapyHIV test on USB stick could be start of consumer revolution in disease monitoringHow to explain the election, Trump and your fears without panicking the kids (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - November 13, 2016 Category: Consumer Health News Source Type: news

Celebrex Is Found to Be No Riskier for Hearts Than Other Pain Drugs
A question has long hung over Celebrex: Did it cause heart attacks? Now, a clinical trial suggests it may be safer than drugs like ibuprofen and naproxen. (Source: NYT Health)
Source: NYT Health - November 13, 2016 Category: Consumer Health News Authors: GINA KOLATA Tags: Celebrex (Drug) Pfizer Inc Clinical Trials Heart Drugs (Pharmaceuticals) Ibuprofen (Drug) Source Type: news

AHA: Study Finds Celebrex Safe for Heart
(MedPage Today) -- But naproxen not as heart safe as believed (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 13, 2016 Category: Geriatrics Source Type: news

Arthritis drug Celebrex may help treat depression, researchers say
Ryan MaassMAYWOOD, Idaho, Nov. 11 (UPI) -- Researchers have found that the arthritis drug celecoxib, often marketed as Celebrex, can help make anti-depression medication more effective. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 11, 2016 Category: Consumer Health News Source Type: news